# A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Source: https://onco.cc/trials/nct04538742/  
OnCo record `nct04538742` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Trastuzumab deruxtecan, Durvalumab, Pertuzumab and Tucatinib in HER2-positive breast cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT04538742 by AstraZeneca, with 245 participants enrolled, started 2020-12-28 and due to reach its primary completion in 2025-01-31. Interventions recorded: Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Pertuzumab and Tucatinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04538742
- Phase: 1/2
- Setting: A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)
- Sponsor: AstraZeneca
- Enrolled: 245

## Sources

- ClinicalTrials.gov NCT04538742: https://clinicaltrials.gov/study/NCT04538742

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Tucatinib](https://onco.cc/drugs/tucatinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct04538742.json